QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=F3F7D600406B02DD75B6184B178BF327;jsessionid=734B308E25BB1D0BF012D5904D21F53D;jsessionid=AA46DBBE4EFBB950F5EB0E10747DF686;jsessionid=71F7F9ECB98699CC31E96882268748B9;jsessionid=695634678EEBA2084C39BEC160FF20BA;jsessionid=FF6C5440DEC8CEC4067DA1B1B44B020A;jsessionid=C799420F1563449C4FD2D622EC295B0E (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. Abnormal open states patterns in the ATXN2 DNA sequence depends on the CAG repeats length.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=F3F7D600406B02DD75B6184B178BF327;jsessionid=734B308E25BB1D0BF012D5904D21F53D;jsessionid=AA46DBBE4EFBB950F5EB0E10747DF686;jsessionid=71F7F9ECB98699CC31E96882268748B9;jsessionid=695634678EEBA2084C39BEC160FF20BA;jsessionid=FF6C5440DEC8CEC4067DA1B1B44B020A;jsessionid=C799420F1563449C4FD2D622EC295B0E